University of Ioannina
Νευρολογικές εκδηλώσεις των αντι-TNF-α παραγόντων σε ασθενείς με ρευματολογικά νοσήματα
Abstract
dc:descriptionTNF-α blockers provide a major advantage in comparison with synthetic (non biological) Disease- Modifying AntiRheumatic Drugs (DMARDs), in the therapeutics of chronic inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthropathies (SpAs), inflammatory intestinal disease, and other inflammatory diseases [1]. Many studies have proved that TNFα blockers suspend further structural damage in a more effective way than DMARDs. Nevertheless, this constantly growing use of the blockers during the past decade has brought to light a series of undesirable consequences due to immune system intermediation [9]. There have been measured clinical symptoms of auto-immune diseases, such as itching (urticaria), psoriasis like rushes, lupus like syndrome, diabetes mellitus type I and other auto-immune disorders [10-13]. Moreover, there have been published numerous reports and cases of undesired neurological findings due to anti – TNF-α drugs use. These include demyelination disease, optic neuritis, chronic inflammatory demyelination polyneuropathy, multiple mononeuritis, Guillain – Barrie yndrome, and other. However, in most of these cases, there is no clear relevance between the anti –TNF-α theurapeutic path and the disease manifestations, because in bibliography the neurologic side effects [as an anti – TNF therapy outcome], could be characterized as ‘’potential’’ and ‘’possible’’, due to the fact that it is not stated whether these disorders pre-existed or the TNF-α blockers led to the them. So, it’s a controversial issue, whether TNF-α blockers therapy brings to surface pre-existing demyelination disorders, like multiple sclerosis (MS), or if they induce de novo demyelinization of Central Nervous System or Peripheral Nervous System. For this reason, we decided to carry out a prospective study using MRI and neurophysiological tests to in patients with RA and SpA who received treatment with TNF-α blockers.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kaltsonoudis, Evripidis
- Καλτσονούδης, Ευριπίδης
Subjects
dc:subject × 16- Νευρολογικές εκδηλώσεις
- anti-TNF-α θεραπεία
- Ρευματοειδής αρθρίτιδα
- Σπονδυλαρθρίτιδες
- Σκλήρυνση κατά πλάκας
- Απομυελίνωση
- Neurologic adverse
- Anti-TNF-α treatment
- Rheumatoid
- Spondyloarthropathies
- Multiple sclerosis
- Demielination
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39000